Fig. 6

Gal-9 preferentially promotes CD26^high CD8⁺ T cells apoptosis in CLL. A Representative plots, and (B) cumulative data of the frequency of CD127⁺/KLRG1⁻ cells among CD26^neg/low/high subsets of CD8⁺ T cells. C Representative plots, and (D) cumulative data of the intensity of Annexin-V expression (MFI) among CD26^neg/low/high CD8⁺ T cells. E Representative plots, and (F) cumulative data of the MFI of CD57⁺ among CD26^neg/low/high CD8⁺ T cells. G Cumulative data of the plasma Gal-9 concentrations in HCs and CLL patients. H Representative plots, and (I) cumulative data of the frequency of CD26^highCD8⁺ T cells following stimulation with anti-CD3/CD28 in the presence or absence of recombinant human Gal-9 (0.02 g\(\mu\)/ml). J Representative plots, and (K) cumulative data of the intensity of Annexin-V expression in CD26^high CD8⁺ T cells following stimulation with anti-CD3/CD28 in the presence or absence of Gal-9. L Cumulative data of Gal-9 concentration in the supernatants of isolated non-B cells versus malignant B cells (B-CLL) after 12 h culture. M Representative plots, and (N) cumulative data ofthe intracytoplasmic MFI of Gal-9 in B cells from HC versus B-CLLs. O Representative plots, and (P) cumulative data of the frequency of Annexin-V expressing CD8⁺ T cells in CD26^high cells at the baseline versus stimulation with a cytokine cocktail (IL-18 + IL-12 + IL-15) (100 ng/ml of each) for 18 h. Error bars represent the median with an interquartile range. Each dot represents an individual human sample